Skip to main content
TipRanks
Go Ultimate75% OFF

Clene (84C0) AI Stock Analysis

1 Followers
DE:84C0

Clene

(Frankfurt:84C0)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
ALS Regulatory ProgressThe ALS NDA submission is a major development milestone that moves CNM-Au8 from clinical development toward potential regulatory review and commercialization. Continued preparation for a confirmatory Phase 3 study also supports the candidate’s strategic importance and development pathway.
Negative Factors
Persistent UnprofitabilityThe company remains deeply unprofitable, with losses far exceeding its small revenue base and negative TTM gross profit. Such stressed economics make a near-term transition to self-funded operations unlikely and leave future value dependent on clinical and regulatory success.

Clene (84C0) vs. iShares MSCI Germany ETF (EWG)

-80%-60%-40%-20%0%20%DE:84C0-60.52%EWG+1.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 50.69M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-1.5
Beta (1Y)
0.75
Revenue Growth
3.08%
EPS Growth
34.10%
Country
Germany
Employees
78
Sector
Consumer Defensive
Sector Strength
62
Industry
Biotechnology

Clene Business Overview & Revenue Model

Company Description

Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship...

Clene Risk Analysis

Clene disclosed 66 risk factors in its most recent earnings report. Clene reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Clene Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

DE:84C0 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
GANXGANX54Neutral$46.75M-2.38-133.17%――33.17%
CGTXCGTX42Neutral$57.12M-3.45-50.57%――62.99%
NRXSNRXS42Neutral$63.87M-4.02-252.10%―94.29%-4.03%
ANVSANVS39Underperform$46.42M-0.43-8312.82%――-15.00%

* Consumer Defensive Sector Average

Performance Comparison

0%100%200%DE:84C0ANVSGANXCGTXNRXSPLYXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:84C0 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:84C0Clene Inc3.04-4.81-61.27%
ANVSAnnovis Bio Inc0.71-3.38-82.62%
GANXGain Therapeutics, Inc.1.00-1.83-64.70%
CGTXCognition Therapeutics, Inc.0.58-0.95-61.96%
NRXSNeurAxis, Inc.4.221.6463.57%
PLYXPolaryx Therapeutics, Inc.1.33-33.67-96.20%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.